158 related articles for article (PubMed ID: 16557569)
1. Understanding urothelial carcinoma through cancer pathways.
Schulz WA
Int J Cancer; 2006 Oct; 119(7):1513-8. PubMed ID: 16557569
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway.
Urakami S; Shiina H; Enokida H; Kawakami T; Tokizane T; Ogishima T; Tanaka Y; Li LC; Ribeiro-Filho LA; Terashima M; Kikuno N; Adachi H; Yoneda T; Kishi H; Shigeno K; Konety BR; Igawa M; Dahiya R
Clin Cancer Res; 2006 Jan; 12(2):383-91. PubMed ID: 16428476
[TBL] [Abstract][Full Text] [Related]
3. The role of WNT signalling in urothelial cell carcinoma.
Ahmad I
Ann R Coll Surg Engl; 2015 Oct; 97(7):481-6. PubMed ID: 26274747
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
5. Study of mutated p53 protein by immunohistochemistry in urothelial neoplasm of urinary bladder.
Roychowdhury A; Dey RK; Bandyapadhyay A; Bhattacharya P; Mitra RB; Dutta R
J Indian Med Assoc; 2012 Jun; 110(6):393-6. PubMed ID: 23360043
[TBL] [Abstract][Full Text] [Related]
6. Evidence for the early onset of aberrant promoter methylation in urothelial carcinoma.
Dhawan D; Hamdy FC; Rehman I; Patterson J; Cross SS; Feeley KM; Stephenson Y; Meuth M; Catto JW
J Pathol; 2006 Jul; 209(3):336-43. PubMed ID: 16639696
[TBL] [Abstract][Full Text] [Related]
7. Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis.
Edamoto Y; Hara A; Biernat W; Terracciano L; Cathomas G; Riehle HM; Matsuda M; Fujii H; Scoazec JY; Ohgaki H
Int J Cancer; 2003 Sep; 106(3):334-41. PubMed ID: 12845670
[TBL] [Abstract][Full Text] [Related]
8. Different combinations of genetic/epigenetic alterations inactivate the p53 and pRb pathways in invasive human bladder cancers.
Sarkar S; Jülicher KP; Burger MS; Della Valle V; Larsen CJ; Yeager TR; Grossman TB; Nickells RW; Protzel C; Jarrard DF; Reznikoff CA
Cancer Res; 2000 Jul; 60(14):3862-71. PubMed ID: 10919661
[TBL] [Abstract][Full Text] [Related]
9. Methylomics analysis identifies ZNF671 as an epigenetically repressed novel tumor suppressor and a potential non-invasive biomarker for the detection of urothelial carcinoma.
Yeh CM; Chen PC; Hsieh HY; Jou YC; Lin CT; Tsai MH; Huang WY; Wang YT; Lin RI; Chen SS; Tung CL; Wu SF; Chang DC; Shen CH; Hsu CD; Chan MW
Oncotarget; 2015 Oct; 6(30):29555-72. PubMed ID: 26320192
[TBL] [Abstract][Full Text] [Related]
10. Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder.
Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
Urol Oncol; 2007; 25(6):468-75. PubMed ID: 18047954
[TBL] [Abstract][Full Text] [Related]
11. Altered mRNA expression of the Rb and p16 tumor suppressor genes and of CDK4 in transitional cell carcinomas of the urinary bladder associated with tumor progression.
Quentin T; Henke C; Korabiowska M; Schlott T; Zimmerman B; Kunze E
Anticancer Res; 2004; 24(2B):1011-23. PubMed ID: 15161057
[TBL] [Abstract][Full Text] [Related]
12. Wnt5a / planar cell polarity signaling pathway in urothelial carcinoma, a potential prognostic biomarker.
Saling M; Duckett JK; Ackers I; Coschigano K; Jenkinson S; Malgor R
Oncotarget; 2017 May; 8(19):31655-31665. PubMed ID: 28427201
[TBL] [Abstract][Full Text] [Related]
13. The Emerging Molecular Landscape of Urothelial Carcinoma.
Solomon JP; Hansel DE
Surg Pathol Clin; 2016 Sep; 9(3):391-404. PubMed ID: 27523968
[TBL] [Abstract][Full Text] [Related]
14. How to combine the molecular profile with the clinicopathological profile of urothelial neoplastic lesions.
van der Kwast TH
Scand J Urol Nephrol Suppl; 2008 Sep; (218):175-84. PubMed ID: 18815932
[TBL] [Abstract][Full Text] [Related]
15. Transient receptor potential vanilloid type 2 (TRPV2) expression in normal urothelium and in urothelial carcinoma of human bladder: correlation with the pathologic stage.
Caprodossi S; Lucciarini R; Amantini C; Nabissi M; Canesin G; Ballarini P; Di Spilimbergo A; Cardarelli MA; Servi L; Mammana G; Santoni G
Eur Urol; 2008 Sep; 54(3):612-20. PubMed ID: 17977643
[TBL] [Abstract][Full Text] [Related]
16. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
17. Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma.
Lindgren D; Sjödahl G; Lauss M; Staaf J; Chebil G; Lövgren K; Gudjonsson S; Liedberg F; Patschan O; Månsson W; Fernö M; Höglund M
PLoS One; 2012; 7(6):e38863. PubMed ID: 22685613
[TBL] [Abstract][Full Text] [Related]
18. Bladder cancer: translating molecular genetic insights into clinical practice.
Cheng L; Zhang S; MacLennan GT; Williamson SR; Lopez-Beltran A; Montironi R
Hum Pathol; 2011 Apr; 42(4):455-81. PubMed ID: 21106220
[TBL] [Abstract][Full Text] [Related]
19. Cell-Intrinsic Tumorigenic Functions of PPARγ in Bladder Urothelial Carcinoma.
Sanchez DJ; Missiaen R; Skuli N; Steger DJ; Simon MC
Mol Cancer Res; 2021 Apr; 19(4):598-611. PubMed ID: 33431608
[TBL] [Abstract][Full Text] [Related]
20. Plasmacytoid urothelial carcinoma of the urinary bladder: clinicopathologic, immunohistochemical, ultrastructural, and molecular analysis of a case series.
Raspollini MR; Sardi I; Giunti L; Di Lollo S; Baroni G; Stomaci N; Menghetti I; Franchi A
Hum Pathol; 2011 Aug; 42(8):1149-58. PubMed ID: 21334719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]